🧪 It highlights the importance of orthogonal detection techniques for identifying oligomers and high molecular weight species.
💡 Expert panelists Karessa White and Bud Halim present high-throughput workflows combining dynamic light scattering and background membrane imaging.
📅 Key takeaways include addressing stability and regulatory concerns during biotherapeutic development.
Introduction:
The article discusses the critical issue of aggregation and the formation of oligomers and high molecular weight species (HMWS) in the biotherapeutic development process. These phenomena pose significant challenges, as they can adversely affect the efficacy, safety, and regulatory approval of biotherapeutic products. The article emphasizes the importance of implementing high-throughput strategies to detect and mitigate these aggregation issues, ensuring the safety and stability of biotherapeutics.
- Aggregation and the formation of oligomers and HMWS are major challenges in biotherapeutics, impacting product safety and regulatory approval.
- Regulatory bodies recommend the use of orthogonal techniques to detect and characterize particles of varying sizes in biotherapeutics.
- The article highlights a systematic approach that integrates dynamic light scattering (DLS) and background membrane imaging (BMI) for characterizing particles across diverse size regimes.
- Orthogonal detection methods provide complementary quantitative and qualitative insights essential for monitoring stability throughout the development process.
- The article discusses practical strategies for monitoring aggregation from early formulations through development and manufacturing to ensure product compliance.
Conclusion:
In summary, the detection and characterization of aggregates in biotherapeutics are vital for achieving stable and safe products. The integration of high-throughput techniques, such as DLS and BMI, can greatly enhance the capacity for identifying and mitigating aggregation issues. As regulatory expectations evolve, the strategies discussed in the article underscore the necessity for continuous improvement and innovation in biotherapeutic development processes.
